melanoma

[Clinical and Experimental Medicine] The efficacy of selumetinib in various solid tumors such as colorectal cancer, lung cancer, neurofibroma, and melanoma is investigated.

[PLoS One] Scientists conducted a study which included 110 melanocytic lesions and three confocal features that were statistically able to distinguish benign melanocytic lesions from melanomas.

[Scientific Reports] Cell cycle analyses revealed a marked G2/M arrest by plasma-activated medium and a clear apoptotic effect by the glycosylated indirubin derivative KD87 in human melanoma A375 and squamous cell carcinoma A431 cell lines.

[EMBO Molecular Medicine] Scientists showed that the anti-fibrotic drug nintedanib was active to normalize the fibrous ECM network, enhanced the efficacy of MAPK-targeted therapy, and delayed tumor relapse in a preclinical model of melanoma.

[Carcinogenesis] Scientists indicated that intermittently blocking TCR signal by tacrolimus could promote anti-tumor immunity and inhibit the tumor growth in melanoma-bearing mice, inhibiting the transcription of several exhaustion-related genes, such as Nr4a1 and Ctla4.

[Journal of Investigative Dermatology] Researchers suggested that Mediator 1 (Med1) inhibited TGF-β signaling pathway to reduce cell epithelial-to-mesenchymal transition phenotype and migration through Smad2 ubiquitination in the metastasis of cutaneous melanoma.